Renalytix LinkedIn Contact Us
Renalytix Investors

Recent Releases

  • Foreign Private Issuer re-qualification
    17 January 2025 07:00 GMT
    read more
  • Grant & Cancellation of Options
    30 December 2024 13:22 GMT
    read more
  • Director/PDMR share purchase
    20 December 2024 16:27 GMT
    read more
  • Result of AGM
    19 December 2024 11:16 GMT
    read more
  • AGM Statement
    19 December 2024 07:00 GMT
    read more

Recent Events

  • Renalytix Third Quarter Fiscal Year 2024 Earnings Call and Webcast
    15 May 2024 08:30 ET
    read more
  • BTIG Conference
    13 February 2024 - 14 February 2024 ET
    read more
  • Renalytix First Quarter Fiscal Year 2024 Earnings Call and Webcast
    17 November 2023 08:30 ET
    read more
  • Renalytix Fourth Quarter Fiscal Year 2023 Earnings Call and Webcast
    28 September 2023 08:30 ET
    read more

Who we are

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs.  Our goal is to lower healthcare costs and improve patient quality of life by transforming the paradigm for kidney disease risk assessment and clinical management through our KidneyIntelX platform.

read more

Company metrics

Leading the market year after year

  • Addressing one of the largest and costliest unmet needs in healthcare
  • Listed on AIM (November, 2018) and OTCQB (October, 2024)
  • FDA Approves KidneyIntelX.dkd™ (June 2023)

Stock performance